Down-regulation of c-myc gene is not obligatory for growth inhibition and differentiation of human myeloid leukemia cells.
Suppression of c-myc expression is observed during induced differentiation of several myeloid cell lines and it has been attributed to the cell growth arrest that accompanies terminal differentiation. To dissect the role of c-Myc in the proliferation-differentiation switch we have studied c-myc expression in K562 cells exposed to several chemical agents. This model system allowed us to discriminate between the growth arrest and differentiation phenomena as well as the induction of differentiation along two different lineages (erythroid and myelomonocytic). Our results showed that c-myc expression did not significantly decrease when growth inhibition is reversible, either by treatment with a differentiating agent such as hydroxyurea (which induced erythroid differentiation) or by a non-differentiating agent such as interferon-alpha. In contrast, c-myc expression decreased when cells underwent terminal differentiation, either along the myelomonocytic (by 12-O-tetradecanoylphorbol-13-acetate) or erythroid (by 1-beta-D-arabinofuranosylcytosine) lineages. These results indicated that c-myc down-regulation is not obligatory for growth arrest and non-terminal differentiation of human myeloid cells. In contrast, c-myc down-regulation occurred in terminal differentiation, but induction of myelomonocytic differentiation resulted in a greater loss of c-myc mRNA than induction of erythroid differentiation.
Gómez-Casares
M T
MT
Departamento de Biologia Molecular, Facultad de Medicine, Universidad de Cantabria, Santander, Spain.
Delgado
M D
MD
Lerga
A
A
Crespo
P
P
Quincoces
A F
AF
Richard
C
C
León
J
J
D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003561:Cytarabine / Q000494:pharmacology; D015536:Down-Regulation / Q000187:drug effects*; D004912:Erythrocytes / Q000473:pathology; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects*; D016259:Genes, myc / Q000187:drug effects*; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology; D016898:Interferon-alpha / Q000494:pharmacology; D007951:Leukemia, Myeloid / Q000235:genetics* / Q000473:pathology; D008264:Macrophages / Q000473:pathology; D008533:Megakaryocytes / Q000473:pathology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000473:pathology
D016898:Interferon-alpha; D003561:Cytarabine; D013755:Tetradecanoylphorbol Acetate; D006918:Hydroxyurea